CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

This study is testing whether giving a PD-1 inhibitor (an immunotherapy drug) as maintenance therapy after completing chemotherapy combined with radiation is safe and effective for people with locally advanced esophageal squamous cell cancer (cancer in the esophagus/food pipe). **You may be eligible if...** - You are 18 or older - You have been diagnosed with squamous cell carcinoma of the esophagus, confirmed by biopsy - Your cancer is locally advanced (stages T3–T4 or lymph node involvement, including possible supraclavicular lymph nodes) - You are in good general health (able to carry out daily activities) with adequate blood and organ function - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You have cancer that has spread to distant organs (except supraclavicular lymph nodes) - You have serious heart, liver, or kidney problems - You have active autoimmune disease or are taking immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.